Document Report Card

Basic Information

ID: ALA4680324

Journal: Bioorg Med Chem Lett

Title: Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.

Authors: Wang Y,Wang C,Zhu Y,Zhang Y,Chen B,Wu Y,Yao J,Miao Z

Abstract: The ATP-adenosine pathway has been recently identified as an attractive immune-oncology target and several drug candidates have been entered clinic trials. Inspired by the report of the first small-molecule CD73inhibitor AB680, we describe the discovery of natural product ellagic acid as a dual CD73 and CD39 inhibitor with an IC value of 1.85 ± 0.21 μM and 0.50 ± 0.22 μM, respectively. The result of cytotoxicity assays indicated that ellagic acid is a valuable lead compound with low cytotoxicity effect for immune therapy.

CiteXplore: 33359608

DOI: 10.1016/j.bmcl.2020.127758